# Adjuvanted Virus-Mimicking Nanoparticle HIV Vaccine

> **NIH NIH N43** · ZYMERON CORPORATION · 2021 · $300,000

## Abstract

Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to develop a novel nanoparticle delivery system to elicit potent and long-lasting antibody response and broadly neutralizing activity against HIV.

## Key facts

- **NIH application ID:** 10441667
- **Project number:** 75N93021C00025-0-9999-1
- **Recipient organization:** ZYMERON CORPORATION
- **Principal Investigator:** XU LI
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $300,000
- **Award type:** —
- **Project period:** 2021-07-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10441667

## Citation

> US National Institutes of Health, RePORTER application 10441667, Adjuvanted Virus-Mimicking Nanoparticle HIV Vaccine (75N93021C00025-0-9999-1). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10441667. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*